These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29369798)

  • 1. Prognostic Role of BRAF
    Abd Elmageed ZY; Moore RF; Tsumagari K; Lee MM; Sholl AB; Friedlander P; Al-Qurayshi Z; Hassan M; Wang AR; Boulares HA; Kandil E
    J Am Coll Surg; 2018 Apr; 226(4):526-537. PubMed ID: 29369798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma.
    Jubb AM; Ribas A; Sosman JA; McArthur GA; Yan Y; Rost S; Zhao S; Koeppen H
    Histopathology; 2013 Sep; 63(3):351-61. PubMed ID: 23802768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
    Xiao J; Egger ME; McMasters KM; Hao H
    BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 8. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF-V600E expression in primary nodular melanoma is associated with aggressive tumour features and reduced survival.
    Hugdahl E; Kalvenes MB; Puntervoll HE; Ladstein RG; Akslen LA
    Br J Cancer; 2016 Mar; 114(7):801-8. PubMed ID: 26924424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
    Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
    Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma.
    Imrédi E; Tóth B; Doma V; Barbai T; Rásó E; Kenessey I; Tímár J
    Melanoma Res; 2016 Jun; 26(3):254-60. PubMed ID: 26848795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A; Quirit JG; Khouri MG; Firestone GL
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
    Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
    Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular and immunohistochemical analysis of BRAF gene in primary cutaneous melanoma: Discovery of novel mutations.
    Fatnassi-Mersni G; Arfaoui AT; Cherni M; Jones M; Zeglaoui F; Ouzari HI; Rammeh S
    J Cutan Pathol; 2020 Sep; 47(9):794-799. PubMed ID: 32285462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.